Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
76.33
-0.57 (-0.74%)
At close: Sep 15, 2025, 4:00 PM EDT
75.03
-1.30 (-1.70%)
After-hours: Sep 15, 2025, 7:36 PM EDT
Halozyme Therapeutics Revenue
Halozyme Therapeutics had revenue of $325.72M in the quarter ending June 30, 2025, with 40.79% growth. This brings the company's revenue in the last twelve months to $1.18B, up 34.97% year-over-year. In the year 2024, Halozyme Therapeutics had annual revenue of $1.02B with 22.44% growth.
Revenue (ttm)
$1.18B
Revenue Growth
+34.97%
P/S Ratio
8.12
Revenue / Employee
$3,367,634
Employees
350
Market Cap
8.93B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.02B | 186.07M | 22.44% |
Dec 31, 2023 | 829.25M | 169.14M | 25.62% |
Dec 31, 2022 | 660.12M | 216.81M | 48.91% |
Dec 31, 2021 | 443.31M | 175.72M | 65.67% |
Dec 31, 2020 | 267.59M | 71.60M | 36.53% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
HALO News
- 7 days ago - Halozyme Therapeutics, Inc. (HALO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 11 days ago - Halozyme Therapeutics, Inc. (HALO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Prepared Remarks Transcript - Seeking Alpha
- 17 days ago - Identify Superstar Stocks Like Halozyme with Money Flows - FXEmpire
- 18 days ago - Halozyme to Participate at Upcoming Investor Conferences - PRNewsWire
- 5 weeks ago - Halozyme Therapeutics, Inc. (HALO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS - PRNewsWire
- 7 weeks ago - European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma - PRNewsWire
- 7 weeks ago - Halozyme to Report Second Quarter 2025 Financial and Operating Results - PRNewsWire